JYMed is pleased to announce that the U.S. Food and Drug Administration has acknowledged receipt of a new Type II Drug Master File for semaglutide API manufactured under a new process. FDA acknowledgment letter for JYMed’s Type II DMF filing for semaglutide API...
A condition may be “rare,” but no person should feel invisible.At JY MedTech, we recognize the resilience of the rare disease community and the importance of continued collaboration across science and healthcare.Today, we stand with patients, families, advocates, and...
From all of us at JYMed Peptide, we wish our customers, partners, and friends around the world a joyful Lunar New Year, filled with good health, happiness, and success. Thank you for your continued trust and collaboration. We look forward to supporting your projects...
Why Sustainable Peptide Manufacturing Is Becoming Essential in Pharma Sustainable peptide manufacturing is rapidly becoming a priority in the pharmaceutical industry. The rapid global expansion of peptide therapeutics in metabolic and chronic disease treatment is...
As part of our semaglutide program, JY MedTech has successfully completed the registration of the semaglutide active pharmaceutical ingredient (API) Korean Drug Master File (K-DMF) in South Korea. The API registration certificate has been issued by the Korean Ministry...
中文
